Advertisement

Topics

Search Results for "CT P6 Celltrion"

21:34 EDT 25th March 2017 | BioPortfolio

Matching Channels

None

Matching News

Celltrion Healthcare IPO Set To Benefit From Biosimilar Successes

Amid Celltrion's string of biosimilar approvals and launches in the US and Europe, its marketing and distribution arm Celltrion Healthcare...   

BRIEF-Celltrion signs 149.10 bln won contract with Celltrion Healthcare

* Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima

Celltrion seeks to introduce more biosimilars in US

More biosimilars from a South Korean drugmaker could join Celltrion's Remicade biosimilar Inflectra, or Remsima, in the US ma -More- 

BRIEF-Celltrion signs contract worth 53.25 bln won

* Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug

Teva to buy Korea's Celltrion?

Biospectrum Celltrion's acquisition will help Teva boost its biosimilars portfolio [Read more]

Teva considers Celltrion purchase to strengthen biosimilar position

Teva Pharmaceutical Industries is exploring the acquisition of South Korea-based Celltrion in its effort to expand its biosim -More- 

Celltrion receives EU approval for Rituxan biosimilar

The European Medicines Agency has approved Celltrion's Truxima, a biosimilar for Roche Holding's leukemia treatment Rituxan/M -More- 

Celltrion submits trastuzumab biosimilar application to EMA

South Korean biotechnology company Celltrion has, according to The Korea Herald, submitted another biosimilar application to the European Medicines Agency (EMA).

Matching PubMed Articles

None

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement